Palifermin for oral mucositis after intensive therapy for hematologic cancers

New England Journal of Medicine

Volumn 351, Issue 25, 2004, Pages 2590-2598

  Spielberger, Ricardo ^a   Stiff, Patrick ^b   Bensinger, William ^c   Gentile, Teresa ^d   Weisdorf, Daniel ^e   Kewalramani, Tarun ^f   Shea, Thomas ^g   Yanovich, Saul ^h   Hansen, Keith ⁱ   Noga, Stephen ^j   McCarty, John ^k   LeMaistre, Frederick ^l   Sung, Eric C ^m   Blazar, Bruce R ^e   Elhardt, Dieter ⁿ   Chen, Mon Gy ⁿ   Emmanouilides, Christos ^m  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c USA   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ Northwest Marrow Transplant Center   (United States)

^j SINAI HOSPITAL OF BALTIMORE   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l TEXAS TRANSPLANT INSTITUTE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; HISTIDINE; KERATINOCYTE GROWTH FACTOR; MANNITOL; MORPHINE; OPIATE; PALIFERMIN; PLACEBO; POLYSORBATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUCROSE; UNCLASSIFIED DRUG;

ADULT; AGEUSIA; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DISEASE; CHEMOTHERAPY; CLINICAL TRIAL; CONDITIONING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ERYTHEMA; EVALUATION AND FOLLOW UP; HUMAN; INTENSIVE CARE; MALE; MOUTH DISEASE; MOUTH MUCOSA; MUCOSA INFLAMMATION; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SORE THROAT; TASTE DISORDER; TONGUE DISEASE; TOTAL PARENTERAL NUTRITION; WHOLE BODY RADIATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEUTROPENIA; PARENTERAL NUTRITION, TOTAL; RADIOTHERAPY; STOMATITIS; TRANSPLANTATION CONDITIONING;

EID: 10344242939     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040125     Document Type: Article

References (33)

1. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993;20:1493-502.
2. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-7.
3. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998;34:39-43.
4. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9.
5. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-5.
6. Armstrong TS. Stomatitis in the bone marrow transplant patient: an overview and proposed oral care protocol. Cancer Nurs 1994;17:403-10.
7. Donnelly JP, Blijlevens NMA, Verhagen CAH. Can anything be done about oral mucositis? Ann Oncol 2003;14:505-7.
8. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 1989;86:802-6.
9. Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58:933-9.
10. Farrell CL, Rex KL, Kaurman SA, et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999;75:609-20.
11. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003;21:1452-8.
12. Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987;69:1015-20.
13. Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2552-8.
14. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in firstcomplete remission. Blood 1993;82:2920-8.
15. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma; value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 1998;16:48-55.
16. Spielberger, RT, Stiff P, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase 2 trial. Proc Am Soc Clin Oncol 2001;20:7a. abstract.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
18. National Cancer Institute common toxicity criteria, version 2.0. April 30, 1999. (Accessed November 19, 2004, at http://ctep. info.nih.gov.)
19. Assessing stomatitis: refinement of the Western Consortium for Cancer Nursing Research (WCCNR) stomatitis staging system. Can Oncol Nurs J 1998;8:160-5.
20. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
21. Landis JR, Heyman ER, Koch GG. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat Rev 1978;46:237-54.
22. Kalbfleisch JD, Prentice PL. The statistical analysis of failure time data. New York: John Wiley, 1980.
23. Lachenbruch PA. Analysis of data with clumping at zero. Biometrische Z 1976;18: 351-6.
24. Kolbinson DA, Schubert MM, Fluomoy N, Truelove EL. Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1988;66:130-8.
25. Zerbe MB, Parkerson SG, Ortlieb ML, Spitzer T. Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs 1992; 15:196-205.
26. Foncuberta MC, Cagnoni PJ, Brandts CH, et al. Topical transforming growth factor-β3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 2001;24:384-8.
27. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001;27:Suppl 2:S3-S11.
28. Antin JH, Lee SJ, Neuberg D, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29:373-7.
29. Dazzi C, Cariello A, Giovanis P, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol 2003;14:559-63.
30. Filicko J, Lazarus HM, Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant 2003;31:1-10.
31. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999;17:2446-53.
32. Sezer O, Eucker J, Metzner B, et al. Mucositis is associated with increased rate of documented infections and treatment-related mortality after high-dose therapy with autologous peripheral stem-cell transplantation. Proc Am Soc Clin Oncol 2000;19: 56a. abstract.
33. Moroni E, Dell'Era, P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res 2002;11:19-32.